Cargando…
Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies
Cell-based cancer immunotherapy has revolutionized the treatment of hematological malignancies. Specifically, autologous chimeric antigen receptor-engineered T (CAR-T) cell therapies have received approvals for treating leukemias, lymphomas, and multiple myeloma following unprecedented clinical resp...
Autores principales: | Li, Yan-Ruide, Dunn, Zachary Spencer, Zhou, Yang, Lee, Derek, Yang, Lili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700013/ https://www.ncbi.nlm.nih.gov/pubmed/34944002 http://dx.doi.org/10.3390/cells10123497 |
Ejemplares similares
-
Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention
por: Li, Yan-Ruide, et al.
Publicado: (2022) -
Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy
por: Li, Yan-Ruide, et al.
Publicado: (2021) -
‘Off the shelf’ immunotherapies: Generation and application of pluripotent stem cell‐derived immune cells
por: Wang, Chenxin, et al.
Publicado: (2023) -
Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
por: Li, Yan-Ruide, et al.
Publicado: (2022) -
‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8(+) T Cells Derived from Hematopoietic Stem Cells
por: Boyd, Nicholas, et al.
Publicado: (2021)